Skip to main content

Advertisement

SpringerLink
Log in

Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference

  • Opioids (J Fiellin and J Donroe, Section Editors)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Opioid use disorder (OUD) is a common diagnosis among incarcerated people. Despite strong evidence for use in correctional facilities, medications for OUD (MOUD) are infrequently used, and when they are, continuity after release is low. Patient preferences regarding treatment in other chronic health conditions can impact outcomes and is an emerging focus in patient-centered research. We review the extent that patient preference is incorporated in MOUD effectiveness studies among incarcerated people and how patient perceptions of MOUD may impact treatment utilization using the Gelberg-Anderson framework for vulnerable populations.

Recent Findings

Of 27 studies of the effectiveness of MOUD among correctional populations, 1 incorporated preference for MOUD in the study design and 5 either noted preference before randomization or elicited perceptions regarding MOUD post hoc. Using the Gelberg-Anderson framework to categorize how patient preference influences MOUD treatment decisions and engagement, there are predisposing, enabling, and needs-based factors, which influence MOUD treatment, including beliefs about medications, social networks, social needs, and perceived MOUD and health needs.

Summary

Few high-quality MOUD effectiveness studies based in jails and prisons have systematically studied patient preference or perspective. Future studies should explicate the role of patient preference in the effectiveness of MOUD treatment and on the impact on treatment engagement and retention during and after incarceration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kaeble D, Cowhig M. Correctional populations in the United States. Washington, DC: Department of Justice; 2016.

    Google Scholar 

  2. Sawyer W, Wagner P. Mass Incarceration: The Whole Pie 2019, Prison Policy Initiative, last modified March 19 2019. https://www.prisonpolicy.org/reports/pie2019.html. Accessed on May 17, 2019.

  3. Bronson J, United States. Bureau of Justice S. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007–2009, 1995–2013. Special report. 2017.

  4. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(50–51):1445–52. https://doi.org/10.15585/mmwr.mm655051e1.

    Article  PubMed  Google Scholar 

  5. Bauch J, Bodurtha P, Leite-Bennett A, Nyren A, Winkelman T, Criminal justice system as a point of intervention to prevent opioid-related deaths: Hennepin County Office of Enterprise Analytics; 2018. https://www.naccho.org/uploads/downloadableresources/38R_1jJUN7avt1b66jTOpioid_Death_Brief.pdf. Accessed on May 17, 2019.

  6. Kuzyk I, Baudoin K, Bobula K. Opioids and criminal justice in CT: Office of Policy & Management, Criminal Justice Policy & Planning Division, Presented June 9 2017. http://cssd.ctclearinghouse.org/images/customer-files-email/1312-CJPAC-OPIOID-PRESENTATION-06092017.pdf. Accessed on May 20, 2019.

  7. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40. https://doi.org/10.1016/j.drugalcdep.2014.05.011.

    Article  CAS  PubMed  Google Scholar 

  8. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103(8):1333–42. https://doi.org/10.1111/j.1360-0443.2008.002238.x.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2–3):220–7. https://doi.org/10.1016/j.drugalcdep.2007.05.022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res. 2010;16(3):139–45. https://doi.org/10.1159/000313336.

    Article  PubMed  Google Scholar 

  11. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1–3):222–30. https://doi.org/10.1016/j.drugalcdep.2008.08.006.

    Article  PubMed  Google Scholar 

  12. Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in-jail methadone maintenance. J Drug Issues. 1993;23(1):75–99.

    Article  Google Scholar 

  13. Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9. https://doi.org/10.1016/S0140-6736(14)62338-2.

    Article  PubMed  PubMed Central  Google Scholar 

  14. •• Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43. https://doi.org/10.1016/j.jsat.2018.12.003. This is an important meta analysis in which the authors document the role of methadone, buprenorphine and injectable naltrexone in increasing post-release community treatment engagement in people who are started on the medications during incarceration. Further, findings highlight the role of methadone in also reducing post release opioid use and injection drug use.

    Article  PubMed  Google Scholar 

  15. Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008–14. https://doi.org/10.1111/add.12894.

    Article  PubMed  Google Scholar 

  16. Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2018;79(1):92–100. https://doi.org/10.1097/QAI.0000000000001759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–43.

    Article  Google Scholar 

  18. Joint Public Correctional Policy on the Treatment of Opioid Use Disorders for Justice Involved Individuals. www.asam.org/resources/publications/magazine/public-policy-statements/2018. 2018. Accessed on May 01, 2019.

  19. Jail-Based Medication-Assisted Treatment: Promising practices, guidelines and resources for the field. www.ncchc.org/jail-based-MAT. 2018. Accessed on May 01, 2019.

  20. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183–90. https://doi.org/10.1001/jama.2008.976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8. https://doi.org/10.1016/j.drugalcdep.2009.06.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18. https://doi.org/10.1080/08897077.2011.611460.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Vestal C. New Momentum for Addiction Treatment Behind Bars. The Pew Charitable Trusts, April 4, 2018. https://www.pewtrusts.org/en/research-andanalysis/blogs/stateline/2018/04/04/new-momentum-for-addiction-treatment-behind-bars. Accessed on May 25, 2019.

  24. • Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD. "I kicked the hard way. i got incarcerated." withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J Subst Abuse Treat. 2016;62:49–54. https://doi.org/10.1016/j.jsat.2015.11.004. In this qualitative study , the authors elicited the negative impact of rapid methadone dose reductions or discontinuation upon incarceration leading to aversion to methadone treatment after release in people who were formerly incarcerated. This study draws attention to the role that penal policy plays in impacting treatment decisions even after incarceration.

    Article  PubMed  Google Scholar 

  25. •• Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, et al. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018;86:104–10. https://doi.org/10.1016/j.addbeh.2018.02.024. The authors present a modified sequential intercept model that is focused on a population that is involved in the criminal justice system. This model presents strategies to prevent overdose risk in people with opioid use disorder who interesect with the criminal justice system even prior to incarceration. The authors support a patient-centered approach to treatment by community corrections in viewing relapse as part of the recovery process.

    Article  PubMed  Google Scholar 

  26. Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285–91. https://doi.org/10.1111/j.1521-0391.2012.12004.x.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, et al. “Don’t judge a book its cover”: a qualitative study of methadone Patients' experiences of stigma. Subst Abuse. 2017;11:1178221816685087. https://doi.org/10.1177/1178221816685087.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zaller ND, Bazazi AR, Velazquez L, Rich JD. Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health. 2009;6(2):787–97. https://doi.org/10.3390/ijerph6020787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17. https://doi.org/10.1111/j.1360-0443.2011.03676.x.

    Article  PubMed  Google Scholar 

  30. Sharma A, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abus Rehabil. 2016;7:27–40. https://doi.org/10.2147/SAR.S81602.

    Article  Google Scholar 

  31. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280(25):1372–5. https://doi.org/10.1056/NEJM196906192802502.

    Article  CAS  PubMed  Google Scholar 

  32. Dolan KA, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev. 1998;17(2):153–8. https://doi.org/10.1080/09595239800186951.

    Article  CAS  PubMed  Google Scholar 

  33. Bellin E, Wesson J, Tomasino V, Nolan J, Glick AJ, Oquendo S. High dose methadone reduces criminal recidivism in opiate addicts. Addict Res. 1999;7(1):19–29.

    Article  Google Scholar 

  34. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.

    Article  Google Scholar 

  35. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–8. https://doi.org/10.1111/j.1360-0443.2005.01050.x.

    Article  PubMed  Google Scholar 

  36. Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM. Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. Drug Alcohol Depend. 2006;83(2):122–9. https://doi.org/10.1016/j.drugalcdep.2005.11.004.

    Article  PubMed  Google Scholar 

  37. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. A study of methadone maintenance for male prisoners: 3-month Postrelease outcomes. Crim Justice Behav. 2008;35(1):34–47. https://doi.org/10.1177/0093854807309111.

    Article  PubMed  PubMed Central  Google Scholar 

  38. McMillan GP, Lapham S, Lackey M. The effect of a jail methadone maintenance therapy (MMT) program on inmate recidivism. Addiction. 2008;103(12):2017–23. https://doi.org/10.1111/j.1360-0443.2008.02361.x.

    Article  PubMed  Google Scholar 

  39. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abus Treat. 2009;37(3):277–85. https://doi.org/10.1016/j.jsat.2009.03.002.

    Article  Google Scholar 

  40. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, et al. A randomized trial of methadone initiation prior to release from incarceration. Subst Abus. 2012;33(1):19–29. https://doi.org/10.1080/08897077.2011.609446.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Macswain M, Farrell-MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (MMT) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2014;41:380–94.

    Article  Google Scholar 

  42. Farrell-MacDonald S, MacSwain MA, Cheverie M, Tiesmaki M, Fischer B. Impact of methadone maintenance treatment on women offenders' post-release recidivism. Eur Addict Res. 2014;20(4):192–9. https://doi.org/10.1159/000357942.

    Article  PubMed  Google Scholar 

  43. Westerberg VS, McCrady BS, Owens M, Guerin P. Community-based methadone maintenance in a large detention center is associated with decreases in inmate recidivism. J Subst Abus Treat. 2016;70:1–6. https://doi.org/10.1016/j.jsat.2016.07.007.

    Article  Google Scholar 

  44. Moore KE, Oberleitner L, Smith KMZ, Maurer K, McKee SA. Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared with forced withdrawal. J Addict Med. 2018;12(2):156–62. https://doi.org/10.1097/ADM.0000000000000381.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ. A randomized clinical trial of buprenorphine for prisoners: findings at 12-months post-release. Drug Alcohol Depend. 2017;172:34–42. https://doi.org/10.1016/j.drugalcdep.2016.11.037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, et al. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12 months post-release. Drug Alcohol Depend. 2018;184:57–63. https://doi.org/10.1016/j.drugalcdep.2017.11.023.

    Article  CAS  PubMed  Google Scholar 

  47. Garcia CA, Correa GC, Viver AD, Kinlock TW, Gordon MS, Avila CA, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med. 2007;1(3):126–32. https://doi.org/10.1097/ADM.0b013e31814b8880.

    Article  CAS  PubMed  Google Scholar 

  48. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abus Treat. 2013;45(2):222–6. https://doi.org/10.1016/j.jsat.2013.02.005.

    Article  Google Scholar 

  49. Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Kulkarni SP, Baldwin S, Lightstone AS, Gelberg L, Diamant AL. Is incarceration a contributor to health disparities? Access to care of formerly incarcerated adults. J Community Health. 2010;35(3):268–74. https://doi.org/10.1007/s10900-010-9234-9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Artenie AA, Minoyan N, Jacka B, Hoj S, Jutras-Aswad D, Roy E, et al. Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. CMAJ. 2019;191(17):E462–E8. https://doi.org/10.1503/cmaj.181506.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients' beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abus Treat. 2016;66:48–53. https://doi.org/10.1016/j.jsat.2016.02.009.

    Article  Google Scholar 

  53. Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs. 2010;42(3):339–46. https://doi.org/10.1080/02791072.2010.10400696.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Lobmaier PP, Kunøe N, Waal H. Treatment research in prison: problems and solutions in a randomized trial. Addict Res Theory. 2010;18(1):1–13. https://doi.org/10.3109/16066350802531273.

    Article  Google Scholar 

  55. Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev 2017;36:305–310. https://doi.org/10.1111/dar.12442

  56. Johnson Q, Mund B, Joudrey PJ. Improving rural access to opioid treatment programs. J Law Med Ethics. 2018;46(2):437–9. https://doi.org/10.1177/1073110518782951.

    Article  PubMed  Google Scholar 

  57. •• Friedrichs A, Spies M, Härter M, Buchholz A. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One. 2016;11(1):e0145817. https://doi.org/10.1371/journal.pone.0145817. An important systematic review showing role for shared decision making and patient preference in the treatment of substance use disorders. Overall results favored use of shared decision making, and patient preferences favored outpatient over inpatient treatment. They point out the heterogeneity of the studies and the need for further research.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zoellner LA, Roy-Byrne PP, Mavissakalian M, Feeny NC. Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. Am J Psychiatry. 2019;176(4):287–96. https://doi.org/10.1176/appi.ajp.2018.17090995.

    Article  PubMed  Google Scholar 

  59. Acuna SA, Chensey TR, Baxter NN. Incorporating Patient Preferences in noninferiority trials. JAMA. 2019;322(4):305–6. https://doi.org/10.1001/jama.2019.7059.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale School of Medicine, Yale University, 367 Cedar Street, Harkness Hall A, Suite 402, New Haven, CT, 06510, USA

    Lisa B. Puglisi & Emily A. Wang

  2. Department of Psychiatry, University of Rochester School of Medicine, Rochester, NY, USA

    Precious S. Bedell

  3. Department of Community and Family Medicine, University of California San Francisco, San Francisco, CA, USA

    Anna Steiner

Authors
  1. Lisa B. Puglisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Precious S. Bedell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily A. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa B. Puglisi.

Ethics declarations

Conflict of Interest

The authors have no conflicts to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Opioids

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Puglisi, L.B., Bedell, P.S., Steiner, A. et al. Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference. Curr Addict Rep 6, 365–373 (2019). https://doi.org/10.1007/s40429-019-00283-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-019-00283-x

Keywords

Search

Navigation